Aprea Therapeutics (APRE) files amendment adding EisnerAmper consent to registration

Rhea-AI Filing Summary

Aprea Therapeutics, Inc. filed Pre-Effective Amendment No. 1 to its registration statement (File No. 333-293609) to furnish an updated consent of EisnerAmper LLP (Exhibit 23.2). The amendment states it does not modify any provision of the prospectus and is limited to filing the updated consent.

The amendment delays effectiveness mechanics remain unchanged and the registrant reiterates customary undertakings and exhibits, including legal opinion of DLA Piper and previously incorporated offering documents.

Insights

Securities Filings Counsel

Pre-effective amendment limited to updated auditor consent; no prospectus changes.

The amendment files an updated Exhibit 23.2 (consent of EisnerAmper LLP) to the Registration Statement, leaving the prospectus unchanged. This is a routine post-filing housekeeping amendment to ensure all required consents are current.

Timing for effectiveness remains governed by the Registration Statement process; subsequent filings will state effectiveness per Section 8(a) if applicable.

Corporate Securities Analyst

Administrative update; no new economic terms or securities quantities disclosed.

The amendment lists exhibits and confirms previously filed documents (forms of warrants, securities purchase agreement, registration rights agreement, legal opinion). It does not present offering sizes, proceeds treatment, or changes to registered securities.

Cash‑flow treatment and registered amounts are not disclosed in this excerpt; any investor impact depends on the underlying registration statement disclosures.

Registration No. 333-293609 

As filed with the Securities and Exchange Commission on March 17, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

AMENDMENT NO. 1 TO
FORM S-3

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

________________________________

APREA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	84-2246769
(State or jurisdiction	(I.R.S. Employer
of incorporation or organization)	Identification No.)

3805 Old Easton Road
Doylestown, PA 18902
(215) 948-4119 

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) 

Oren Gilad, Ph.D.
President and Chief Executive Officer
Aprea Therapeutics, Inc.
3805 Old Easton Road
Doylestown, PA 18902
(215) 948-4119 

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) 

Copies to:

Fahd M.T. Riaz, Esq.
Patrick O’Malley, Esq.
DLA Piper LLP (US)
1650 Market Street, Suite 5000
Philadelphia, PA 19103-7300
(212) 839-5599 

Approximate date of commencement of proposed sale to the public:
From time to time after this registration statement becomes effective. 

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: x

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ¨

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer x	Smaller reporting company x
Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ¨

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

Explanatory Note

This Pre-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-293609) (the “Registration Statement”) of Aprea Therapeutics, Inc. (the “Company”) is being filed solely to file an updated consent of EisnerAmper (Exhibit 23.2) to the Registration Statement. This Amendment No. 1 does not modify any provision of the Prospectus that forms a part of the Registration Statement and accordingly such Prospectus has not been included herein.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16.   Exhibits

Exhibit No.	​	Description
3.1*	​	Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Report on Form 8-K filed on October 7, 2019).
3.2*	​	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Aprea Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 13, 2023).
3.3*	​	Certificate of Designation of Series A Non-Voting Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 17, 2022).
3.4*	​	Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed on November 6, 2020).
4.1*	​	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on January 29, 2026).
4.2*	​	Form of Common Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed on January 29, 2026).
5.1**	​	Opinion of DLA Piper LLP (US).
10.1*+	​	Form of Securities Purchase Agreement, dated as of January 28, 2026, by and between Aprea Therapeutics, Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 29, 2026).
10.2*	​	Form of Registration Rights Agreement, dated as of January 28, 2026, by and between Aprea Therapeutics, Inc. and the purchasers (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on January 29, 2026).
23.1**	​	Consent of DLA Piper LLP (US) (included in Exhibit 5.1).
23.2	​	Consent of EisnerAmper LLP.
24.1**	​	Power of Attorney (located on the signature page of the Registration Statement on Form S-3, filed on February 20, 2026).
107**	​	Filing fee table.

*Previously filed.

**Previously filed as an exhibit to the Company’s Registration Statement on Form S-3, filed on February 20, 2026.

+

Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Doylestown, Commonwealth of Pennsylvania, on March 17, 2026.

	APREA THERAPEUTICS, INC.
	By:	/s/ Oren Gilad
		Oren Gilad, Ph.D.
		President, Chief Executive Officer and Director
		(Principal Executive Officer)
		/s/ John P. Hamill
		John P. Hamill
		Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

POWER OF ATTORNEY

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated on the date indicated:

Signature		Title		Date
/s/ Oren Gilad		President, Chief Executive Officer and Director		March 17, 2026
Oren Gilad, Ph.D.		(Principal Executive Officer)
/s/ John P. Hamill		Senior Vice President and Chief Financial Officer		March 17, 2026
John P. Hamill		(Principal Financial Officer and Principal Accounting Officer)
/s/ *		Director		March 17, 2026
Marc Duey
/s/ *		Director		March 17, 2026
Michael Grissinger
/s/ *		Director		March 17, 2026
John B. Henneman III
/s/ *		Director		March 17, 2026
Rifat Pamukcu, M.D.
/s/ *		Director		March 17, 2026
Richard Peters, M.D., Ph.D.
/s/ *		Director		March 17, 2026
Gabriel Gruia, M.D.
/s/ *		Director
Bernd R. Seizinger, M.D., Ph.D.				March 17, 2026
/s/ *		Director
Jean-Pierre Bizzari, M.D.				March 17, 2026

*By:	/s/ Oren Gilad
Oren Gilad, Ph.D.
Attorney-in-fact

FAQ

What does Aprea Therapeutics' (APRE) Amendment No. 1 do?

It files an updated EisnerAmper LLP consent (Exhibit 23.2) to the registration statement. The amendment states the prospectus is unchanged and only the auditor consent was updated for filing completeness.

Does the amendment change the prospectus or offering terms for APRE?

No. The filing explicitly states the amendment does not modify any provision of the prospectus. It is limited to furnishing an updated auditor consent and housekeeping exhibits.

Does the amendment state how much stock APRE is registering?

No. The amendment lists exhibits and consents but does not disclose any registered amount or offering size in the provided excerpt. Registered quantities are in the underlying registration statement.

Which exhibits are newly included or emphasized in this amendment?

The amendment adds the updated Exhibit 23.2 (Consent of EisnerAmper LLP) and reiterates previously filed exhibits such as the legal opinion of DLA Piper (Exhibit 5.1) and the filing fee table (Exhibit 107).

Will this amendment by itself make the registration statement effective?

No. The amendment does not state an effectiveness date; it preserves the registrant's undertaking to delay effectiveness until a further amendment specifies the effective date under Section 8(a).